Kymera Therapeutics, Inc.
KYMR
$25.97
$0.953.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.23% | -48.56% | 13.38% | -237.95% | 72.82% |
| Total Depreciation and Amortization | 0.00% | 2.53% | 32.65% | 63.97% | -0.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.64% | 9.31% | -25.33% | 43.54% | -7.75% |
| Change in Net Operating Assets | -265.71% | 92.61% | -107.92% | -153.11% | 20.29% |
| Cash from Operations | -23.10% | -16.89% | -8.45% | -592.12% | 125.42% |
| Capital Expenditure | -595.24% | 104.03% | 36.65% | 36.33% | -43.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 144.03% | -876.49% | 106.29% | -1,157.02% | -55.42% |
| Cash from Investing | 143.49% | -1,108.06% | 104.73% | -1,844.44% | -68.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 54.29% | -82.10% | -21.38% | -131.35% | 372.06% |
| Issuance of Common Stock | -87.51% | 14,160.71% | -99.50% | 34,988.80% | 652.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.90% | 17,670.40% | -99.60% | 18,191.42% | 1,038.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -77.82% | 266.32% | -57.41% | -156.83% | 0.95% |